# US 2020/0370068 A1 · Methods for preventing and treating type ii diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0370068 A1
- Document ID: US20200370068A1
- Status: Published application
- Kind: A1
- Application number: 16/966,287
- Filed: 2019-01-31
- Published: 2020-11-26
- Earliest claimed: 2018-01-31
- Assignees: The Jackson Laboratory
- Applicants: The Jackson Laboratory
- Inventors: Michael Stitzel
- Web page: https://patentgrep.com/patent/US20200370068A1

## CPC

- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A61K 38/28: Insulins
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/907: {in mammalian cells}
- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- A01K 2267/0362: Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
- C12N 2015/8527: {for producing animal models, e.g. for tests or diseases}
- C12Q 2600/156: Polymorphic or mutational markers
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein, in some aspects, are methods for preventing or treating diabetes in a subject, the method comprising assaying a genomic sample obtained from the subject for an intergenic variant located in a region between a C2 calcium-dependent domain containing 4A gene (C2CD4A) and a C2 calcium-dependent domain containing 4B gene (C2CD4B), and when the intergenic variant is present in the genomic sample, administering to the subject a therapy for diabetes. Also provided herein are rodent cells homozygous for a C2cd4a mutation and/or homozygous for a C2cd4h mutation, and methods for producing the rodent cells.

## Claims

### Claim 1

A cell in a transgenic animal, the cell comprising an inactivated C2 calcium-dependent domain containing 4A (C2cd4a) gene, an inactivated C2 calcium-dependent domain containing 4B (C2cd4b) gene, or an inactivated C2cd4a gene and an inactivated C2cd4b gene.

### Claim 2 (depends on 1)

The cell of claim 1, wherein the inactivated C2cd4a gene and/or the inactivated C2cd4b gene comprises a deletion.

### Claim 3 (depends on 2)

The cell of claim 2, wherein transgenic animal is a mouse, and optionally wherein the mouse is a NZO/HILtJ mouse.

### Claim 4

A cell comprising an inactivated C2 calcium-dependent domain containing 4A (C2cd4a) gene, an inactivated C2 calcium-dependent domain containing 4B (C2cd4b) gene, or an inactivated C2cd4a gene and an inactivated C2cd4b gene.

### Claim 5 (depends on 1, 2, 3, 4)

The cell of any one of claims 1-4, wherein a genotype of the cell is C2cd4a−/−.

### Claim 6 (depends on 1, 2, 3, 4)

The cell of any one of claims 1-4 wherein a genotype of the cell is C2cd4b−/−.

### Claim 7 (depends on 1, 2, 3, 4)

The cell of any one of claims 1-4, wherein a genotype of the cell is C2cd4cd4a−/−/C2cd4b−/−.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The cell of any one of claims 1-7, wherein the inactivated C2cd4a gene and/or the inactivated C2cd4b gene comprises a deletion.

### Claim 9 (depends on 8)

The cell of claim 8, wherein the cell is a rodent cell, and optionally wherein the rodent cell is a mouse cell.

### Claim 10 (depends on 9)

The cell of claim 9, wherein the mouse cell is a NZO/HILtJ mouse cell.

### Claim 11 (depends on 4, 5, 6, 7, 8, 9, 10)

An animal comprising the cell of any one of claims 4-10.

### Claim 12 (depends on 11)

The animal of claim 11, wherein the animal is a rodent.

### Claim 13 (depends on 12)

The animal of claim 12, wherein the rodent is a mouse.

### Claim 14 (depends on 11, 12, 13)

The animal of any one of claims 11-13, wherein the animal is a transgenic animal.

### Claim 15

A method for producing a C2cd4a−/− rodent cell, the method comprising:
introducing into the rodent cell a gRNA or a nucleic acid encoding a gRNA that targets a C2cd4a gene, wherein (a) the cell expresses a Cas nuclease, (b) the method further comprises activating expression of a Cas nuclease in the cell, or (c) the method further comprises introducing into the cell a Cas nuclease or a nucleic acid encoding a Cas nuclease;
optionally culturing the cell; and
producing the C2cd4a−/− rodent cell.

### Claim 16 (depends on 15)

The method of claim 15 further comprising introducing into the C2cd4a−/− rodent cell a gRNA or a nucleic acid encoding a gRNA that targets a C2cd4b gene, wherein (a) the C2cd4a−/− rodent cell expresses a Cas nuclease, (b) the method further comprises activating expression of a Cas nuclease in the C2cd4a−/− rodent cell, or (c) the method further comprises introducing into the C2cd4a−/− rodent cell a Cas nuclease or a nucleic acid encoding a Cas nuclease;
optionally culturing the C2cd4a−/− rodent cell; and
producing a C2cd4a−/−/C2cd4b−/− rodent cell.

### Claim 17

A method for producing a C2cd4b−/− rodent cell, the method comprising:
introducing into the rodent cell a gRNA or a nucleic acid encoding a gRNA. that targets a C2cd4b gene, wherein (a) the cell expresses a Cas nuclease, (b) the method further comprises activating expression of a Cas nuclease in the cell, or (c) the method further comprises introducing into the cell a Cas nuclease or nucleic acid encoding a Cas nuclease;
optionally culturing the cell; and
producing the C2c4b−/− rodent cell.

### Claim 18 (depends on 14)

The method of claim 14 further comprising introducing into the C2cd4b−/− rodent cell a nucleic acid encoding a gRNA that targets a C2cd4a gene, wherein (a) the C2cd4b−/− rodent cell comprises a Cas nuclease, (b) the method further comprises activating expression of a Cas nuclease in the C2cd4b−/− rodent cell, or (c) the method further comprises introducing into the C2cd4b−/− rodent cell a Cas nuclease or a nucleic acid encoding a Cas nuclease;
optionally culturing the C2cd4b−/− rodent cell; and
producing a C2cd4a−/−/C2cd4b−/− rodent cell.

### Claim 19

A method for producing a C2cd4a−/−/C2cd4b−/− rodent cell, the method comprising:
introducing into the rodent cell a nucleic acid encoding a gRNA that targets a C2cd4a gene and a nucleic acid encoding a gRNA that targets a C2cd4b gene, wherein (a) the cell expresses a Cas nuclease, (b) the method further comprises activating expression of a Cas nuclease in the cell, or (c) the method further comprises introducing into the cell a Cas nuclease or a nucleic acid encoding a Cas nuclease;
optionally culturing the cell; and
producing the C2cd4a−/−/C2cd4b−/− rodent cell.

### Claim 20 (depends on 15, 16, 17, 18, 19)

The method of any one of claims 15-19, herein the rodent cell is a rodent islet beta cell.

### Claim 21 (depends on 15, 16, 17, 18, 19, 20)

The methodf any one of claims 15-20, wherein the rodent cell is a mouse cell.

### Claim 22 (depends on 21)

The method of claim 21, wherein the mouse cell is from a NZO/HILtJ mouse.

### Claim 23 (depends on 21)

The method of claim 21, wherein the mouse cell is an mouse embryonic stem cell.

### Claim 24 (depends on 23)

The method of claim 23 further comprising introducing the mouse embryonic stem cell into an inner cell mass of a murine blastocyst.

### Claim 25 (depends on 24)

The method of claim 24 further comprising implanting the blastocyst in the uterus of a female mouse.

### Claim 26 (depends on 25)

The method of claim 25 further comprising identifying heterozygous offspring of the female mouse that have a C2cd4a−/+, C2cd4b−/+, or C2cd4a−/+/C2cd4b−/+ genotype.

### Claim 27 (depends on 25)

The method of claim 25 further comprising mating heterozygous offspring of the female mouse to produce a homozygous mouse having a C2cd4a−/+, C2cd4b−/+, or C2cd4a−/+/C2cd4b−/+ genotype.

### Claim 28

A mouse cell homozygous for a C2cd4a mutation and homozygous for a C2cd4b mutation, optionally wherein the mouse cell is from a NZO/HILtJ mouse.

### Claim 29

A method for preventing or treating diabetes in a subject, the method comprising:
assaying a genomic sample obtained from a subject for a single nucleotide polymorphism (SNP) selected from rs4502156 allele (T), rs1881415 allele (T), rs67818839 allele (A), rs7162757 rs8037894 allele (G), rs8038040 allele (G), rs6494307 allele (C), rs7161785 allele (G), rs7167878 allele (C), rs7167932 allele (C), rs7172432 allele (A), rs7173964 allele (G), rs4775466 allele (C), rs4775467 allele (G), rs10083587 allele (C), and rs11856307 allele (A); and
when the SNP is present in the genomic sample, administering to the subject a therapy to prevent or treat diabetes in the subject.

### Claim 30

A method for preventing or treating diabetes in a subject, the method comprising:
assaying a genomic sample obtained from a subject for an intergenic variant located in a region between a C2 calcium-dependent domain containing 4A (C2CD4A) gene and a C2 calcium-dependent domain containing 4B (C2CD4B) gene;
measuring a level of proinsulin in a biological sample obtained from the subject; and
when the intergenic variant is present in the genomic sample and the level of proinsulin in the biological sample is greater than 20 pmol/L, administering to the subject a therapy to prevent or treat diabetes in the subject.

### Claim 31 (depends on 29, 30)

The method of claim 29 or 30, wherein the therapy comprises administering to the subject an agent that reduces expression and/or activity of C2CD4A protein and/or C2CD4B protein.

### Claim 32 (depends on 29, 30)

The method of claim 29 or 30, wherein the therapy comprises administering to the subject an agent that reduces calcineurin (Cn)/NTAT pathway activity.

### Claim 33 (depends on 29, 30)

The method of claim 29 or 30, wherein the therapy comprises administering insulin therapy to the subject.

### Claim 34 (depends on 30, 31, 32, 33)

The method of any one of claims 30-33, wherein the intergenic variant is a SNP selected from rs4502156 allele (T), rs1881415 allele (T), rs67818839 allele (A), rs7162757 allele (C), rs8037894 allele (G), rs8038040 allele (G), rs6494307 allele (C), rs7161785 allele (G), rs7167878 allele (C), rs7167932 allele (C), rs7172432 allele (A), rs7173964 allele (G), rs4775466 allele (C), rs4775467 allele (G), rs10083587 allele (C), and rs11856307 (A).

### Claim 35 (depends on 29, 34)

The method of claim 29 or 34, wherein the SNP is rs7163757 allele (C).

### Claim 36 (depends on 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 29-35, wherein the subject has or is at risk of type II diabetes.

### Claim 37 (depends on 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 29-36, wherein the genomic sample is a DNA sample.

### Claim 38 (depends on 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 30-37, wherein the biological sample is a blood sample.

### Claim 39 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 29-38, wherein the assaying step comprises sequencing the genomic sample.

### Claim 40

A transgenic mouse comprising an inactivated C2 calcium-dependent domain containing 4A (C2cd4a) gene, an inactivated C2 calcium-dependent domain containing 4B (C2cd4b) gene, or an inactivated C2cd4a gene and an inactivated C2cd4b gene.

### Claim 41 (depends on 40)

The transgenic mouse of claim 40, wherein the inactivated C2cd4a gene comprises a deletion, the inactivated C2cd4b gene comprises a deletion, or the inactivated C2cd4a gene and the inactivated C2cd4b gene each comprise a deletion.

### Claim 42 (depends on 40, 41)

The transgenic mouse of claim 40 or 41, wherein the inactivated C2cd4a gene and/or the inactivated C2cd4b gene are inactivated within islet beta cells.
